A Multicenter Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma

Trial Profile

A Multicenter Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Famitinib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FACT
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 16 Apr 2018 Planned End Date changed from 31 Dec 2017 to 1 Jun 2019.
    • 16 Apr 2018 Planned primary completion date changed from 30 Nov 2017 to 1 Nov 2018.
    • 30 May 2017 Planned End Date changed from 1 Jul 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top